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Early detection and characterization of molecular events associated with tumorgenesis 
remain high priorities. Genome-wide epigenetic assays are promising diagnostic tools, 
as aberrant epigenetic events are frequent and often cancer specific. The deposition 
and analysis of multiple patient-derived cancer epigenomic profiles contributes to 
our appreciation of the underlying biology; aiding the detection of novel identifiers 
for cancer subtypes. Modifying enzymes and co-factors regulating these epigenetic 
marks are frequently mutated in cancers, and as epigenetic modifications themselves 
are reversible, this makes their study very attractive with respect to pharmaceutical 
intervention. Here we focus on the novel modified base, 5-hydoxymethylcytosine, and 
discuss how genome-wide 5-hydoxymethylcytosine profiling expedites our molecular 
understanding of cancer, serves as a lineage tracer, classifies the mode of action of 
potentially carcinogenic agents and clarifies the roles of potential novel cancer drug 
targets; thus assisting the development of new diagnostic/prognostic tools.
First draft submitted: 15 September 2016; Accepted for publication: 14 October 2016; 
Published online: 12 December 2016
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Cancer is now largely accepted as being 
both a genetic and epigenetic disease as 
specific tumor types are frequently found 
to harbor common sets of genetic muta-
tions as well as recurrent changes to the 
epigenetic landscape [1,2]. Although epi-
genetic control of gene expression is related 
to the overall phenotypic output of a cell 
and dysregulation of epigenetic signals has 
been associated with cancer, whether or not 
these epigenetic changes are causal or sim-
ply reflective of signaling driven changes is 
still under debate [3,4]. Enzymes and protein 
complexes which are associated with the 
regulation of epigenetic patterns are among 
the most frequently mutated genes in many 
cancer types – indicating that genetic dis-
ruptions of these epigenetic landscapes may 
be associated either with the initiation and/
or the progression of cancer [1,5–7]. Never-
theless these nonsequence based alterations 
are considered as viable cancer driver alter-
natives to chromosomal alterations and 
mutations [8]. It is widely accepted that 
deregulation of normal DNA modifica-
tion and gene expression patterns can aid 
cancer cells to evolve more rapidly, gener-
ating intratumoral heterogeneity and thus 
contribute to increased invasiveness, meta-
static potential and potentially drug resis-
tance [9,10]. These observations have been 
further strengthened by results from the 
International Cancer Genome Consortium 
(ICGC) whose genome-wide sequencing 
of a large cohort of cancers has provided a 
catalogue of common somatic mutations in 
the coding regions of numerous epigenetic 
regulators [11].
In the mammalian genome the bulk of 
the epigenetic DNA modifications (70–
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80%) occur within a CpG dinucleotide (Cytosine-
phosphate-Guanine), the majority of which include a 
methylated cytosine base (5-methylcytosine, [5mC]) 
and are found at relatively low densities throughout 
the genome [12]. Methylated CpG dinucleotides are 
typically associated with heterochromatic portions 
of the genome and also have roles in phenomenon 
such as imprinting, X-inactivation and transcriptional 
silencing of genes and retrotransposons [13,14]. High 
density nonmethylated CpGs occur as CpG Islands 
(CGIs), which are typically associated with promoter 
regions of actively and potentially active transcribing 
genes. Unmodified CpGs can be converted to 5mC 
through the actions of a group of enzymes known 
as the DNA methyltransferases (the maintenance 
methyltransferase DNMT1, and the de novo meth-
yltransferases DNMT3a and 3b). These same 5mC 
marks can be converted back to an unmodified state, 
through inhibition of DNA methyltransferases and 
the action of a series of methylcytosine dioxygen-
ase enzymes known as the Ten-Eleven-Translocases 
(TETs 1, 2 and 3) that can generate intermediates in 
a potential DNA demethylation pathway; 5-hydroxy-
methylcytosine (5hmC), 5-formylcytosine (5fC) and 
5-carboxylcytosine (5CaC) (Figure 1A) [15-16]. The 
former of these of modified bases, 5hmC, has gath-
ered much interest in recent years due to the fact that 
its stable relative abundance would predict that its 
roles may be more purposeful than simply acting as a 
DNA demethylation intermediate [17]. 5fC and 5caC 
can be further excised by thymine-DNA glycosylase 
(Tdg) to allow the restoration of unmodified C by the 
base excision and repair machinery (Figure 1A) [18,19]. 
Oocyte-specific Tdg conditional knockout gives rise 
to normal offspring which do not exhibit altered levels 
of zygotic 5hmC, which may indicate the existence 
of other demethylation mechanisms downstream of 
5mC oxidation [20,21].
Recent advances in genome-wide sequencing strat-
egies combined with reduced costs, the accessibility 
of equipment and growing bioinformatics expertise 
are opening up new avenues of research for academic, 
clinical and industrial research [22], most evidently in 
the cancer field where studies are routinely carried out 
to define genetic mutations associated with particular 
cancer subtypes [23]. However in many cancers, tumor-
igenesis is not always directly related to a clear set of 
genetic abnormalities but is also linked to changes in 
the epigenetic landscape [24]. In this review we will 
focus on how recent genome-wide 5hmC studies have 
advanced our understanding of cancer at the molecular 
level and advocate how such studies could further aid 
in the identification of novel cancer drug targets and 
the development of new diagnostic tools.
Active DNA demethylation & 5hmC
Active DNA demethylation pathways can be medi-
ated through the activity of the TET enzymes 
(TET1, 2 and 3) in which 5mC bases are converted 
to 5-hydroxymethyl marked bases by oxidation in an 
iron and alpha-ketoglutarate dependent manner [15,25] 
(Figure 1B). Changes in TET activity has been sug-
gested to be linked with altered 5mC patterns in many 
cancers; a hot topic is delineating how perturbation of 
this pathway may contribute to cancer initiation and 
progression [26–30]. Although less abundant in abso-
lute terms than 5mC (between 0.1 and 0.7% of all 
cytosines) the levels of 5-hydroxy-marked cytosines 
are far greater than the downstream DNA demeth-
ylation modifications; 5-formylcytosine (5fC) and 
5-carboxylcytosine (5caC) representing approximately 
20 × 10-6% cytosine for 5fC and 3 × 10-6% cytosine 
for 5caC in mouse embryonic stem (ES) cells, indicat-
ing that while 5fC and 5CaC may represent transient 
and ongoing DNA demethylation, the more abundant 
5hmC may also have a functional role throughout the 
genome [31,32].
A myriad of work has revealed that both the global 
levels as well as the patterns of the modifications vary 
greatly between tissue and cell types – highlight-
ing that fact that 5hmC can be used as an identifier 
of cell or tissue type [33]. The consensus view is such 
that 5hmC modified CpGs are generally depleted over 
the majority of promoter elements but are enriched 
over the bodies of transcriptionally active genes 
and enhancer elements as well as a small number of 
transcriptional starts sites associated with silenced 
genes [34,35] (Figure 1C). This contrasts with 5mC 
profiles which are present genome wide and enriched 
at satellite and repeat DNA sequences [34]. Proximal 
enrichment of 5hmC at enhancers upstream of anno-
tated transcriptional start sites suggests a role for these 
regions in the regulation of gene expression [36]. The 
distribution of particular histone modifications around 
genes is strongly overlapping with peaks of 5hmC in 
normal tissues, for example active enhancer marks, 
H3K4me1/H3K27ac, are associated with 5hmC at 
regions flanking transcription start sites [37,38]. The fact 
that 5hmC profiles are related to the transcriptional 
landscape means that it is a far more dynamic modifi-
cation than 5mC – which is typically thought of as a 
stable lock on inactive chromatin states. In addition, 
sequencing studies in ES cells correlates the presence 
of 5fC and 5caC with hypomethylated promoters of 
highly expressed genes, which is increased upon Tdg 
silencing, indicating the presence of an active DNA 
demethylation pathway on these promoters [39]. These 
regions were found to be methylated by Dnmt1 and 
Dnmt3a, and demethylated by a Tet-dependent mech-
10.2217/epi-2016-0122www.futuremedicine.com
Figure 1. Active DNA demethylation and 5-hydroxymethylcytosine patterns in normal and cancer cells. (A) Overview of the DNA 
methylation/active demethylation cycle. (B) Schematic of the structures of the human TET enzymes. CXXC: domain which can bind 
directly to unmodified CpG dinucleotides, Cys: cysteine-rich domain, DSBH: double-stranded β-helix domain including binding sites 
for Fe(II) and 2-OG cofactors. (C) Activation of gene expression can occur through the active demethylation of regions around the 
transcription start sites (loss of 5mC through a 5hmC intermediate) with elevated promoter proximal and genic 5hmC levels allowing 
the binding and elongation of the RNAP-II complex, probably in concert with histone modification changes (not shown). Conversion 
of 5mC into 5hmC (and further derivatives) is mediated by the TET proteins (blue). TET proteins have been shown to interact with 
OGT as well as HCF1, component of the H3K4 methyltransferase SET1/COMPASS complex, resulting in altered chromatin environments 
(OGT, HCF1 & SET1 complex = Yellow). Thymine DNA glycosylase, TDG, (not shown) is proposed to complete this promoter specific 
demethylation through base excision repair while regions lacking TDG lead to the accumulation of 5hmC (such as gene bodies and 
enhancers), perhaps by tracking the RNA Pol II complex in the case of gene bodies. Typical 5hmC (blue) and 5mC (red) profiles at 
an actively transcribing gene are shown below with patterns observed in cancer shown as an overlay. (D) Review of methods by 
which Tet enzyme levels or activity may be altered and how these may be related to perturbed epigenetic landscapes in cancer. 
5hmC: 5-hydroxymethylcytosine; HCF1: Host Cell Factor 1; OGT: O-GlcNAc transferase.
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anism [39]. Thus inhibition of Tet function may influ-
ence the CGI promoters of both active and repressed 
genes and this may also be relevant to downregulation 
of tumor suppressor genes in cancer.
DNA modification perturbations in cancer
Disruption of epigenetic landscapes, including 5hmC 
and 5mC patterns, is a hallmark of cancer [1,8,10,37,40]. 
Although the underlying mechanisms of cancer-spe-
cific methylation changes are still largely unclear, it is 
apparent that they occur early in both cancer initia-
tion and progression [41]. In cancerous tissues, DNA 
methylation patterns are often drastically different 
from those found in the normal healthy tissue. Three 
major epigenetic alterations are frequently observed in 
cancer: global DNA hypomethylation in cancer across 
large domains and affecting repetitive DNA sequences, 
global hypo-hydroxymethylation across the majority of 
the genome including over promoters and gene bodies 
and discrete gene-specific hypermethylation of CGIs, 
CGI shores and enhancer elements affecting hundreds 
of loci [26,42–45]. Given the robust interplay that 5mC and 
5hmC exhibit, the observed changes in each modifica-
tion throughout cancer are dynamically linked [46–48]. 
For the scope of this review we will focus mainly on 
the study of 5hmC patterns during carcinogenesis in 
the context of global  hypo-hydroxymethylation and 
discrete hypermethylation.
Global hypo-hydroxymethylation
The 5hmC modification has been studied across a 
host of cancers both at the gross global level as well 
as in more detail by investigating genome-wide pat-
terns [37,49–52]. These studies, most commonly using 
immunohistochemistry, dot blot assay and mass 
spectroscopy, consistently report a strong global loss 
of 5hmC in tumors, in a host of cancer cell lines [33], 
human and mouse hepatocellular carcinomas [45,48,53], 
human gastric cancers [54], renal cell carcinomas [55], 
acute myeloid leukemia [56] and melanomas [57]. Cen-
tral to the reduction in global 5hmC levels is the fact 
that the enzymes responsible for generating 5hmC 
from 5mC – the TET enzymes – as well as several of 
their co-factors, are often mutated, transcriptionally 
downregulated or reduced at the protein level [30,48,58]. 
Current data suggest that there exists substantial 
amount of 5hmC overlap deposited by the three mem-
bers as evidenced by the finding that Tet-1, -2 or -3 
null mice are viable and that loss of 5hmC is not abso-
lute in Tet1 null mouse livers [48,59]. Short hairpin 
RNA (shRNA) reduction of each of the TET enzymes 
in human embryonic carcinoma cells has shown that 
loss of TET1 resulted in the greatest elevation of 5mC 
at promoter elements as well as widespread reduc-
tion of 5hmC, while depletion of TET2 and TET3 
reduces 5hmC at a subset of TET1 targets suggesting 
some functional co-dependence [60]. All TETs pre-
vent hypermethylation throughout the genome, par-
ticularly at CpG island shores where loss of all three 
TETs was related to hypermethylation events [37,45,61]. 
Loss of 5hmC at enhancers in Tet2-/- mouse ES cells 
resulted in their hypermethylation and impacted on 
gene expression during early stages of ES cell differen-
tiation [62]. This implies that alterations in enhancer 
function via epigenetic perturbation may affect gene 
expression during tumorigenesis.
The gene encoding TET1 was first identified as 
fusion partner of the mixed lineage leukemia (MLL1) 
gene in patients with acute myeloid leukemia [63]. TET1 
binds preferentially to CGIs via a CXXC domain 
and is frequently disrupted (either transcriptionally 
silenced or reduced in activity) during the progression 
of cancer, while re-expression in lung and colon can-
cer cells inhibits the proliferation and growth of tumor 
xenografts suggesting an important regulatory role 
during carcinogenesis [27,64]. Although specific muta-
tions within the TET1 gene have not been directly 
associated with cancer progression, reduced transcrip-
tional and/or protein levels of TET1 has been reported 
in colon, gastric, lung and liver cancers while TET2 
transcription/protein levels are more typically reduced 
in leukemia and melanoma [27,46,53,57,65–67] (Figure 1D). 
Mutation in key cell surface receptors such as oncogenic 
epidermal growth factor receptor (EGFR) can result in 
the repression of TET1, but not TET2 or TET3, via 
the transcription factor C/EBPα which in turn induces 
silencing of a series of tumor suppressors in lung can-
cer and glioblastoma cells [64]. TET1 downregulation 
has also been shown to promote malignancy in breast 
cancer and to act as a tumor suppressor that can inhibit 
colon cancer growth by de-repressing inhibitors of the 
WNT pathway [27,65,68–70]. Interestingly TET1 is itself 
found both methylated and transcriptionally repressed 
in a series of cell lines and primary tumors of multiple 
carcinomas and lymphoma, although whether or not 
the methylation is itself causative or reflective of TET 
transcriptional inactivation is still to be fully eluci-
dated [29,65]. However as mutations in TET1 are very 
infrequently found in cancer, particularly compared 
with TET2 in leukemia, signal induced epigenetic 
silencing may be an alternative method by which TET 
and 5hmC levels are reduced in cancer.
Aside from genetic or transcriptomic perturbation, 
the activity of TET enzymes can be inhibited or stimu-
lated in the presence of particular co-factors, metabo-
lites and post-translational modifications (Figure 1D). 
This is most evident in a series of leukemias, glioblas-
tomas and cholangiocarcinomas in which individuals 
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harbor mutations in the genes IDH1 and IDH2 – the 
Krebs cycle enzymes isocitrate dehydrogenase 1 and 2 
– responsible for the conversion of alpha ketoglutarate 
(αKG) into 2-hydroxyglutarate (2HG). These muta-
tions result in overactive IDH1/2 enzymes which in turn 
results in elevated 2HG which inhibits TET catalytic 
activity [46]. In addition to the IDH1 and 2 enzymes, 
mutations in two other Krebs cycle proteins, fumarate 
hydratase (FH) and succinate dehydrogenase (SDH), 
are relatively common in a subset of human cancers 
including Gastrointestinal stromal tumors (3–8% of 
SDH cases), renal cell carcinomas (1–4% of SDH and 
71–93% of FH cases) and paraganglioma (12–15% of 
SDH cases) [71–73]. Mutations in FH and SDH lead to 
an accumulation of fumarate and succinate which can 
inhibit multiple αKG-dependent dioxygenases, includ-
ing the TET family of enzymes. In contrast it has been 
shown that increasing the levels of ascorbic acid (vita-
min C) stimulates TET protein enzymatic activity 
in both cultured cells as well as mouse tissues [74,75]. 
Although the precise mechanism is currently unknown 
it is believed that vitamin C interacts with the catalytic 
domain of the TET enzymes resulting in a localized 
reduced environment favoring efficient binding of the 
Iron (Fe[II]) co-factor. The activity of TET enzymes 
can also be reduced by tumor hypoxia in human and 
mouse cells, which occurs independently of hypoxia-
associated alterations in TET expression and depends 
directly on oxygen shortage [30]. This can result in 
increased hypermethylation at gene promoters in vitro; 
patients exhibit markedly more methylation at selected 
promoters in hypoxic tumor tissue that is independent 
of proliferation, stromal cell infiltration and tumor 
characteristics. Increased hypoxia in mouse breast 
tumors results in hypermethylation, while restoration 
of tumor oxygenation abrogates this effect. Taken 
together these results highlight the complex relation-
ship between 5hmC disruption and cancer progression 
that is not only reliant directly on the transcriptional 
state of the TET enzymes but the overall environment 
in the  cancer cell (Figure 1D).
In concert with a reduced global level during car-
cinogenesis, genome-wide patterns of 5hmC are also 
strongly altered between tumor samples and normal 
surrounding tissue [37,45,48,57,61]. In melanoma, there is 
both loss and gain of genic 5hmC at a large number of 
genes – although the changes in 5mC were far more 
subtle than for 5hmC. These genes tended to be asso-
ciated with melanoma related pathways, Wnt signaling 
components and not surprisingly general cancer pro-
gression. By reinstating normal levels of expression of 
the TET enzymes it was possible to somewhat restore 
the normal 5hmC landscape, resulting in increased 
tumor-free survival in a zebrafish model of mela-
noma [57]. In lung and liver cancers the specific rela-
tionship between 5hmC and sets of chromatin marks 
present in normal tissue is largely absent in tumors, 
which may drive or reflect altered regulation of gene 
expression [37].
Discrete hyper-methylation events in cancer
Typically, hyper-methylation events occur at either 
normally un-methylated CGI promoters, CGI 
‘shores’ (the regions up to 2kb away from a CGI) 
or gene regulatory enhancer elements [37,43–44,48,76]. 
The mechanisms by which these cancer-associated 
epigenetic patterns arise are still debated however 
recent evidence suggests that disruption of the nor-
mal DNA methylation/demethylation cycle during 
carcinogenesis may be responsible for aberrant CGI 
hyper-methylation events [10]. Inactivation of TET1 
is associated with hematopoietic malignancy in 
which loss of 5hmC and/or gain of 5mC on promot-
ers in TET1−/− cells may result in downregulation of 
expression and derailment of the differentiation pro-
cess [77]. Of interest is the observation that oncogenic 
KRAS can inhibit TET1 expression via the ERK-
signaling pathway; restoration of TET1 expression 
by ERK pathway inhibition or ectopic TET1 rein-
troduction in KRAS-transformed cells reactivates 
a select number of target genes [29]. This indicates 
a dichotomy between signaling-induced regulation 
of methylation of a discrete number of CGI target 
genes and generalized tissue determined CpG island 
methylator profiles that are variable within tumor 
types [10,78]. In the latter case, de novo methylation 
occurs predominately at already silenced genes (pas-
senger genes) and there does not affect their expres-
sion status while in the former, silencing by DNA 
methylation of select target genes is dependent on an 
active signaling pathway and therefore is not epigen-
etic in character [29,40]. Oncogenic RAS- or BRAF-
directed transcriptional silencing of tumor suppres-
sor genes is not truly epigenetic because the activated 
oncogene is required for both initiation of the path-
way and maintenance of repression [3–4,79]. This con-
sideration leads to two questions: how do tumor sup-
pressor genes become methylated and how is DNA 
methylation of tumor suppressor genes inherited 
through multiple generations [78]? One suggestion 
would be that DNA methylation at tumor suppres-
sor genes is not epigenetically inherited, but is main-
tained by an instructive transcriptional mechanism 
that can potentially repress multiple genes. In con-
trast, we have recently shown that the aberrant CGI 
hyper-methylation in several mouse models of liver 
cancer occurs at sites marked by a unique chromatin 
state in the healthy liver [48]. The promoter proximal 
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sites destined to become hyper-methylated in liver 
cancer were found to be rich in 5hmC and associ-
ated with ‘bivalently’ marked histone tail modifica-
tions (H3K27me3 and H3K4me3), which are typi-
cally associated with a transcriptionally poised but 
not active states. We observe loss of 5hmC occurs 
at these sites prior to accumulation of 5mC and this 
is related to a reduction in the levels of the TET1 
enzyme, which has previously been shown to bind 
preferentially to CGIs. Loss or reduced binding of 
TET1 from these CGIs would ultimately result in a 
loss of active, ‘protective’ DNA  demethylation and 
acquisition of 5mC.
Although aberrant hyper-methylation at CGIs is 
often invoked as a mechanism causing the transcrip-
tional inactivation of tumor suppressor genes that 
directly drives the carcinogenic process, many of the 
genes associated with hypermethylated CGIs in cancer 
are already silent in the host tissue to begin with [40,48]. 
Emerging data reveal that changes in 5mC over 
enhancer elements may instead be more related to the 
phenotypic and transcriptomic changes observed dur-
ing cancer progression [37]. In recent studies enhanc-
ers are consistently the most differentially methylated 
regions during the progression from normal tissue to 
primary tumors and then to metastases, compared 
with other genomic features, and changes in the 5mC 
levels at these loci were linked to cancer type as well 
as the overall patient outcome [37,44]. Future focus on 
such loci will be key to unravelling the role of DNA 
methylation and hydroxymethylation disruption dur-
ing cancer progression [36]. In addition, the anticancer 
effects of DNA methyltransferase inhibitors has been 
linked with upregulation of immune signaling in can-
cer through the viral defense pathway, independently 
of CpG island methylator profiles [80,81]. Upregula-
tion of hypermethylated endogenous retrovirus genes 
accompanies the response and endogenous retrovirus 
overexpression activates the response. Interferon path-
way genes were also upregulated by the DNMT inhibi-
tor, 5-Azacytidine (AZA), and this was correlated with 
increased expression of endogenous retroviral tran-
scripts rather than de-repression of  interferon pathway 
transcription factors [80,81].
Applications of genome-wide 5hmC studies 
in cancer research
The rapid development of genome-wide sequencing-
based technologies is resulting in an ever growing 
number of studies across a broad range of research 
areas [22]. Currently the bulk of genome-wide 5hmC 
datasets are either generated through affinity-based 
methods (antibody or chemical capture – see [35]) or 
emerging single base resolution-based strategies which 
can differentiate 5mC from 5hmC [37,82–83]. Although 
incredibly informative, these latter approaches require 
between 50 and 100× coverage to accurately call 
5hmC content and as such are both costly and data 
heavy. Bioinformatic pipelines are in development 
to extract usable information based on 15X cover-
able using single nucleotide resolution methods [37]. 
Here we highlight the utility of 5hmC-based assays 
– particularly those centered on antibody-based 
5-hydroxmethyl DNA immuno precipitation or hme-
DIP – to both aid in the understanding of how cancer 
progresses at the molecular level as well as how such 
research can impact on the development of diagnostic 
tools and therapeutic strategies (Figure 2).
5hmC ‘barcoding’ to identify carcinogenic 
compounds
As discussed above, 5hmC patterns are dynamic, tis-
sue specific and strongly perturbed during disease 
progression [84]. We have previously reported that 
in the mouse liver that promoter 5hmC patterns 
can reflect both acute and chronic exposure to car-
cinogenic agents in a model of nongenotoxic carci-
nogenesis [84–86]. In addition, a global decrease in 
the level of 5hmC was noted following subchronic 
exposures to the genotoxic carcinogens riddelliine 
and aristolochic acid in rat liver [87]. Thus, 5hmC can 
be regarded as an ‘identifier of cell type or disease 
state,’ with specific 5hmC patterns dependant on the 
length of time of exposure to a carcinogenic agent. 
Through administration of the anticonvulsant Phe-
nobarbital (PB), we noted a number of time depen-
dant gene body and regulatory region changes in the 
liver hydroxymethylome with only modest changes 
observed in the methylome. Importantly, these time 
dependant changes were reproducible across indi-
vidual mice – highlighting the potential robustness 
of 5hmC analysis for industrial and clinical-based 
assays using isogenic animal models. Changes in 
genome-wide 5hmC patterns were far more effi-
cient at stratifying exposed animals from the control 
cohort than analysis of 5mC modifications [85,86]. A 
series of genes exhibited a strong elevation in their 
genic 5hmC level, some of which have well defined 
roles in the metabolism of drugs such as PB; the 
cytochrome P450s Cyp2b10 and Cyp2c55 (Figure 2B). 
Others were related to key signaling pathways associ-
ated with cancer progression such as Wisp1 (WNT1 
inducible signaling pathway protein 1) and the non-
coding RNA cluster Dlk1/Dio3 [85,88–89]. As such, 
analysis of 5hmC perturbations in the drug exposed 
animal can result in the identification of novel 
drug/disease specific biomarkers as well as giving 
an insight into the molecular mechanisms for how 
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Figure 2. Overview of antibody-based 5-hydroxymethylcytosine genome-wide sequencing strategy and downstream analytical 
routes. Genomic DNA (gDNA) is isolated from the host organ/tumor and fragmented to a desired size range. Following enrichment 
of 5hmC marked DNA fragments by hydroxymethyl-DNA-immunoprecipitation (hmeDIP), sequencing libraries can be prepared 
and genome-wide sequencing carried out. Following bioinformatic processing, regions of differential 5hmC modification can be 
identified which can lead to: (i) increased understanding of molecular mechanisms, (ii) identification of diagnostic, (iii) or cancer 
specific (patient stratification) biomarkers and (iv) identification of novel therapeutic targets.  
5hmC: 5-hydroxymethylcytosine.
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particular compounds promote tumorigenesis. Ulti-
mately, using genome-wide based approaches it may 
be possible to generate 5hmC ‘barcodes’ (digital out-
puts unique to a given drug exposure/disease state) 
in which loci exhibiting reproducible 5hmC change 
can be compared with healthy tissues (normal 5hmC 
patterns), as well as to a catalogue of barcodes gener-
ated through exposure to different compounds, some 
of which may be carcinogenic (Figure 3A). Through 
the comparative analysis of 5hmC barcodes it will be 
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Figure 3. Applications of 5-hydroxymethylcytosine ‘barcoding’ in cancer research. (A) Schematic examples for 
how epigenetic ‘barcoding’ based on genome-wide 5hmC patterns can aid in the stratification of novel drug 
compounds depending on potential carcinogenic outcome. (B) Schematic for how 5hmC ‘barcoding’ could be 
applied to identify a series of epigenetic changes which occur prior to the observation of a tumor. In doing so 
it may be possible to stratify patients into cohorts based on their specific cancer subtype which would aid in 
downstream personal medicine regimes.  
5hmC: 5-hydroxymethylcytosine.
Healthy
tissue
“Pre-
neoplastic”
Tumour
Diagnostic 5hmC “barcoding”
Early diagnosis/patient stratication
“Personalised medicine”
Pharmaceutical 5hmC “barcoding”
H
ea
lth
y
D
ru
g 
1
D
ru
g 
2
D
ru
g 
3
D
ru
g 
4
Drug being tested
A
ssociated w
ith tum
ours
A
ssociated w
ith tum
ours
future science group
Review    Thomson & Meehan
possible to delineate the response of novel drug com-
pounds and through analysis of 5hmC changes pre-
dict the likelihood that a given drug will result in a 
carcinogenic effect in the host. Such approaches may 
be particularly useful in satisfying the 3Rs (replace, 
reduce and refine) in both general scientific studies 
and industrial toxicity testing screens.
5hmC profiling to aid in the identification of 
novel therapeutic targets & strategies
As the epigenome is often dramatically altered in 
cancer there has been much interest in linking these 
perturbations with the identification of novel drug 
targets. It is critical to learn if the reinstatement of 
normal epigenetic patterns is coincident with disease 
reversal. Identification of genes exhibiting strong 
5hmC changes has the potential to identify novel 
therapeutic targets, while the study of 5hmC patterns 
using in vitro or in vivo models in which potential 
tumor suppressor genes or oncogenes are mutated or 
removed can give a novel insight into their function. 
For example, the enzyme TET1 has been defined as a 
tumor suppressor that inhibits both colon cancer and 
hematopoietic malignancies [27,77] and, as described 
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Figure 4. Genome-wide 5-hydroxymethylcytosine analysis as a diagnostic tool in cancer. Examples for how 5hmC-
based studies can aid in probing of molecular events that occur in metastasis, resulting in the identification of 
primary tumor sites distinct from metastatic samples or be adapted for novel early stage diagnostic tools through 
the study of circulating tumor cells in the bloodstream.  
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above, is along with TET2 and TET3 responsible 
for the conversion of 5mC to 5hmC in mamma-
lian systems. TET1 activity is lost in several cancer 
types, including liver cancer, and has been linked to 
increased proliferation and metastatic potential in 
human gastric cancer [66]. We have previously shown 
through genome-wide sequencing in Tet1 deficient 
mice that a global reduction in the levels of 5hmC 
occurs in mutant liver compared with its healthy wild-
type counterpart [48]. As the re-expression of TET1 
in colorectal cancer cells results in a reduction in 
the number of tumors in mouse xenografts it will be 
important to study if such recovery is directly related 
to a restoration of epigenetic state. One potential 
therapeutic strategy is centered on the TET enzyme 
co-factor vitamin C, which has been found to increase 
the activity of the TET enzymes [74,75]. In a recent 
study, Gustafson et al. found that treatment of mela-
noma cell lines with vitamin C at relatively physiolog-
ical doses increased the level of 5hmC and decreased 
tumor-cell  invasiveness [90].
Application of diagnostic 5hmC-based studies 
in personalized cancer treatment regimes
The identification of novel biomarkers that can define 
specific cancer subtypes at an early stage remains 
a high priority in oncology. The dynamic nature of 
5hmC during cancer progression reveals its utility in 
understanding how cancers develop as well as identify-
ing different cancer types. 5hmC holds both prognos-
tic and diagnostic value – as shown in recent studies 
for both prostate cancer and gliomas where a global 
reduction in the mark was associated with poor prog-
nostic outcomes [53,91–93]. Application of genome-wide 
sequencing assays to such samples would give a valu-
able insight into the epigenetic changes occurring in 
particular cancer subtypes and aid in the identifica-
tion of novel early stage diagnostic biomarkers. We 
have previously shown that during the progression of 
three independent mouse liver cancers (either PB drug 
exposed, Ha-Ras mutated or nonalcoholic fatty liver 
disease-associated hepatocellular carcinomas) that 
although global promoter core hypo-hydroxymeth-
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Figure 5. Overview of how studies utilizing genome-wide 5-hydroxymethylcytosine profiling can advance the field of cancer 
research. 5hmC-based analysis can aid both the understanding of the underlying mechanisms associated with cancer progression, 
identify novel diagnostic tools and result in the development of new therapeutic strategies for cancer treatment.  
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ylation/hyper-methylation is a hallmark of cancer 
progression, there are a number of unique epigenetic 
perturbations linked to specific tumor pathologies. 
Such a result reinforces the possibility that combined 
epigenetic analysis may allow the stratification of par-
ticular tumor subtypes [40,94–95] and may be a useful 
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diagnostic tool in humans [45]. Epigenetic ‘barcod-
ing’ may be able to identify particular subtypes of a 
given cancer, which will allow for stratification and 
assessment toward downstream clinical treatment 
regimens (Figure 3B). Application of similar studies to 
test the 5hmC patterns in circulating tumor cells in 
the serum of blood samples may provide novel early 
stage diagnostic tools while investigating 5hmC land-
scapes at isolated metastatic samples may be able to 
identify an unknown primary tumor site based on 
epigenetic perturbations common to particular tumor 
types (Figure 4).
The potential for epigenetic-based studies to refine 
clinical decision-making holds great promise. Indeed 
in a recent small study of oncosupplgenic EGFR lung 
cancers it was reported that individuals who exhib-
ited resistance to EGFR tyrosine kinase inhibitors 
did not express the TET1, unlike the tyrosine kinase 
inhibitors responsive samples, which instead exhibited 
elevated TET1 levels [64]. Such a study highlights the 
importance for further tests establishing the utility 
of TET1 expression – and expansion to investigate 
5hmC patterns in resistant individuals – to define bio-
markers for predicting responses to cancer  therapeutic 
agents.
Conclusion
The discovery of the dynamic DNA modification, 
5hmC, has provided mechanistic insights into the 
process of DNA methylation reprogramming that 
accompanies cellular transformation of multiple 
cancer types. At the same time, using genetically 
similar mouse models, it has proved to be a potential 
read out of physiological and environmental induced 
changes in tissue status. Whether this is applicable 
to genetically diverse human populations, experienc-
ing multiple exposure environments remains to be 
assessed. However 5hmC profiling has proved to be 
efficacious in tracking and describing the epigenetic 
dysregulation associated with human tumor samples. 
It provides additional data for integrative pathway 
analysis (IPA) that may correlate with documented 
phenotypic, pathological, genetic and molecular out-
comes to better describe disease states [96]. Is it possi-
ble that there are characteristic epigenetic disruption 
signatures that remain after exposure to a disruptive 
agent? Resolution of these questions will aid in the 
development of improved biomarkers and eventual 
therapies.
Future perspective
Genome-wide epigenetic-based assays continue to 
hold tremendous potential toward both the enhance-
ment of our understanding of cancer progression at 
the molecular level as well as in the development of 
new diagnostic screens with direct clinical utility. 
Not only are these epigenetic patterns strongly altered 
during the early stages of cancer progression, emerg-
ing evidence suggests that these are specific to partic-
ular cancer types – highlighting the potential utility 
in stratification of patients into optimal downstream 
treatment regimes. Linking these stratifications with 
genetic studies will be important. There may be 
SNPs associated with specific epigenomic responses 
that link to enhancer or topological chromatin orga-
nization [38]. Unlike genetic mutations which are 
encoded in the DNA sequence – epigenetic patterns 
are potentially reversible. As such the development of 
refined drugs that restore normal epigenetic patterns 
are of great interest in the field of cancer research, 
as they hold great promise as effective treatments in 
combined therapies [80,81]. Combining genome-wide 
epigenetic-based assay with cutting edge technologies 
– such as recent advances in CRISPR–Cas9 technolo-
gies which allow researcher to manipulate the epigen-
etic states of specific loci [97] – will be pivotal in driv-
ing future research into cancer  progression and in the 
identification of novel  cancer therapies.
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